LON:HCM HUTCHMED (HCM) Share Price, News & Analysis GBX 166.50 -5.75 (-3.34%) As of 07/24/2026 11:54 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About HUTCHMED Stock (LON:HCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HUTCHMED alerts:Sign Up Key Stats Today's Range 166▼ 17450-Day Range 156▼ 18252-Week Range 150.48▼ 292Volume37,564 shsAverage Volume36,914 shsMarket Capitalization£1.43 billionP/E Ratio3.14Dividend Yield4.63%Price TargetN/AConsensus RatingN/A Company Overview We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13). Read More Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesHUTCHMED (LON:HCM) Stock Crosses Below 200-Day Moving Average - Time to Sell?July 21, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (HCM), Axsome Therapeutics (AXSM) and Vertex Pharmaceuticals (VRTX)July 8, 2026 | theglobeandmail.comBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.July 26 at 1:00 AM | Decentralized Masters (Ad)HUTCHMED (China) (HCM) Gets a Buy from UBSJuly 4, 2026 | theglobeandmail.comHUTCHMED Announces China Conditional Approval of ORPATHYS for MET-Amplified Advanced Gastric CancerJuly 2, 2026 | quiverquant.comQHUTCHMED to Announce Interim Results for Six Months Ended June 30, 2026 on July 30, 2026June 30, 2026 | quiverquant.comQHUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026June 24, 2026 | markets.businessinsider.comHUTCHMED Announces Positive Phase II Results for Fanregratinib in FGFR2-Altered Intrahepatic CholangiocarcinomaJune 24, 2026 | quiverquant.comQSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at GBX 209 at the beginning of 2026. Since then, HCM stock has decreased by 20.3% and is now trading at GBX 166.50. How do I buy shares of HUTCHMED? Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include Associated British Foods (ABF), Chaarat Gold (CGH), Bank of America (BAC), Fossil Group (FOSL), AMC Entertainment (AMC) and Air Canada (AC). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:HCM CIKN/A Webwww.chi-med.com Phone+85221213888FaxN/AEmployees1,760Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 53 Trailing P/E Ratio3.14 Forward P/E Ratio34.34 P/E GrowthN/ANet Income-£52.98 million Net Margins163.84% Pretax MarginN/A Return on Equity36.88% Return on Assets-5.90% Debt Debt-to-Equity Ratio7.91 Current Ratio4.96 Quick Ratio2.97 Sales & Book Value Annual Sales£548.51 million Price / Sales2.61 Cash FlowGBX 66.74 per share Price / Cash Flow2.49 Book ValueGBX 87.44 per share Price / Book1.90Miscellaneous Outstanding Shares859,752,000Free FloatN/AMarket Cap£1.43 billion OptionableNot Optionable Beta0.43 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:HCM) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredThe pact that ran the world and dollar just expiredIn 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...Golden Portfolio | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
